Achievements span sustainability, social and governance initiatives

Revvity, Inc. (NYSE: RVTY) today released its annual Impact Report, a comprehensive reflection of the Company’s sustainability, social and governance strategy, initiatives and performance. This year’s report, Progress with Purpose: Science and Sustainability, highlights the Company’s strengthened partnerships, product innovation, sustainability driven investments and other efforts aimed at advancing science and human health responsibly.

“Early in our sustainability journey, we established ambitious, but realistic goals to guide our progress in efforts that would positively impact people and the planet. In just one year since our inaugural Impact Report, our team has eclipsed our waste reduction goal and continues to make considerable advances across other key areas,” said Prahlad Singh, president and chief executive officer at Revvity. “Looking ahead, we’re confident in our ability to navigate complexity and deliver results as we create a lasting, meaningful impact for our customers, colleagues, shareholders and communities.”

The 2025 Impact Report highlights the Company’s progress in advancing its responsible business philosophy and operations, with key achievements including:

• Achieving 6% reduction in year-over-year Scope 1 and 2 emissions in 2024, reflecting a 14% cumulative reduction compared to 2022 baseline levels.
• Achieving 49% of non-hazardous waste diverted from landfills in 2024, surpassing the Company’s goal of 40% by 2027.
• Earning a AAA ESG rating from MSCI, the highest possible score, recognizing leadership in managing sustainability risks and opportunities. 
• Completing our first double materiality assessment with results shaping our disclosures, strategy, and sustainability priorities in the future.
• Expanding Revvity Access STEM Scholarships to global universities, including Fudan University in China, and Trinity Hall at the University of Cambridge in the UK.
• Recognition as a Great Place to Work^® in the U.S., India, Poland and China, reflecting the Company’s supportive, inclusive and thriving workplace for all.

To learn more about Revvity’s commitments and progress visit esg.revvity.com.

About Revvity

At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.

With 2024 revenue of more than $2.7 billion and approximately 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 160 countries.

Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251013366439/en/